People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s Wegovy.

Pharmaceutical company Eli Lilly’s study of its tablet, orforglipron, has raised hopes of an effective and easy-to-use treatment reaching a market dominated by injections.

(The most famous example is Prozac.) To be clear, the word "orforglipron" won't appear on Eli Lilly's consumer-facing packaging if it ever hits the market. It's the drug's generic name, so it ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...